KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Net Income towards Common Stockholders: 2014-2024

Historic Net Income towards Common Stockholders for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Dec 2024 value amounting to $5.7 million.

  • Aurinia Pharmaceuticals' Net Income towards Common Stockholders rose 120.53% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.9 million, marking a year-over-year increase of 443.39%. This contributed to the annual value of $5.7 million for FY2024, which is 107.36% up from last year.
  • Aurinia Pharmaceuticals' Net Income towards Common Stockholders amounted to $5.7 million in FY2024, which was up 107.36% from -$78.1 million recorded in FY2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' Net Income towards Common Stockholders peaked at $5.7 million during FY2024, and registered a low of -$181.0 million during FY2021.
  • For the 3-year period, Aurinia Pharmaceuticals' Net Income towards Common Stockholders averaged around -$60.2 million, with its median value being -$78.1 million (2023).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 76.24% in 2021, then skyrocketed by 107.36% in 2024.
  • Over the past 5 years, Aurinia Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at -$102.7 million in 2020, then crashed by 76.24% to -$181.0 million in 2021, then soared by 40.22% to -$108.2 million in 2022, then increased by 27.83% to -$78.1 million in 2023, then skyrocketed by 107.36% to $5.7 million in 2024.